Drug Trial Radar · NCT07157007
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Sep 16, 2025
Primary completion
Feb 16, 2026
Study completion Feb 16, 2026
Sponsor
- Lead sponsor
- Traws Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.
Conditions
- COVID - 19
Interventions
Ratutrelvir (83-0060) non-randomisedDrug
83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)
PaxlovidDrug
Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor)
Ratutrelvir (83-0060)Drug
83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety based on adverse events incidenceTime frame: 28 days
- Safety based on adverse events severityTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Institute of Virology
Tashkent, Tashkent, Uzbekistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.